From the Blood Journals

From the Blood Journals

Research from the Blood family of journals: Blood and Blood Advances

WIB_icon

Remission Duration Key to Survival in CLL After FCR

In spite of the efficacy of the treatment regimen of fludarabine, cyclophosphamide, and rituximab (FCR) in chronic lymphocytic leukemia (CLL), most CLL patients are...
WIB_icon

Once-Weekly Bortezomib Produced Durable Responses, Survival in Relapsed AL Amyloidosis

Results from a phase I/II study of single-agent bortezomib suggest that a once-weekly dosing regimen produced similar efficacy results to a twice-weekly regimen —...
WIB_icon

The Earlier the Better Early Response to Imatinib Predicted Outcomes in Children with CML

While imatinib has been proven effective for the majority of pediatric patients with chronic myeloid leukemia (CML), 13 to 25 percent of children still...
WIB_icon

Moderate-Dose Cyclophosphamide for Severe Aplastic Anemia:Potential Toxicity Outweighs Potential Benefit

While cyclophosphamide at high or more moderate doses can be active in severe aplastic anemia, a new study published in Blood reveals that a...
WIB_icon

New Target Holds Potential for Treatment of Common Anemia

Lexaptepid, an anti-hepcidin therapy, may be the first viable treatment option for patients with anemia of inflammation, according to the results of an experimental...
Advertisement

Current Issue

October 2019, Volume 5, Issue 12

This issue highlights the unintended consequences of fighting the nation’s opioid epidemic, considers the optimal frontline regimen for myeloma, and more.